WE CLAIM:

1. A compound of formula I:

2.



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

X is $-C(R^4)=$ or $-N=$;

Ar is phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^1 and R^2 are independantly hydrogen or C_1-C_3 alkyl;

R^3 is hydrogen, fluoro, or methyl;

when X is $-C(R^4)=$, R^4 is hydrogen, fluoro, or methyl, provided that no more than one of R^3 and R^4 may be other than hydrogen; and

R^5 is hydrogen, methyl, or ethyl.

2. The compound according to Claim 1 wherein Ar is phenyl or substituted phenyl.

3. The compound according to any one of Claims 2 wherein Ar is substituted phenyl and wherein the phenyl group is substituted with one to three halo substituents; or

substituted with one to two substituents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, cyano, and nitro, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently one to five halo groups each independently selected from fluoro and chloro.

4. The compound according to Claim 2 wherein Ar is substituted phenyl and wherein the phenyl group is substituted with 1 to 3 halo groups.

5. The compound according to Claim 1 wherein Ar is heterocycle or substituted heterocycle, wherein the heterocycle is selected from the group consisting of furanyl, thiophenyl, pyrrolyl, pyridinyl, *N*-methylpyrrolyl, pyrimidinyl, pyrazinyl, benzofuranyl, benzothiophenyl, and indolyl; and

wherein substituted heterocycle is taken to mean the ring moiety is substituted with one to three halo substituents; or

substituted with one to two substituents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, cyano, and nitro, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently one to five halo groups each independently selected from fluoro and chloro.

6. The compound according to any one of Claims 1 - 5 wherein R^5 is hydrogen.

7. The compound according to any one of Claims 1 – 6 wherein R^1 and R^2 are methyl.

8. A pharmaceutical composition comprising a compound according to any one of Claims 1 - 7 and a pharmaceutical carrier, diluent, or excipient.

9. A method for activating 5-HT_{1F} receptors in a mammal comprising administering to a mammal in need of such activation an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

X is $-C(R^4)=$ or $-N=$;

Ar is phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^1 and R^2 are independantly hydrogen or C_1-C_3 alkyl;

R^3 is hydrogen, fluoro, or methyl;

when X is $-C(R^4)=$, R^4 is hydrogen, fluoro, or methyl, provided that no more than one of R^3 and R^4 may be other than hydrogen; and

R^5 is hydrogen, methyl, or ethyl.

10. The method according to Claim 9 wherein the mammal is a human.

11. A method for inhibiting dural protein extravasation in a mammal comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

X is $-C(R^4)=$ or $-N=$;

Ar is phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^1 and R^2 are independantly hydrogen or C_1-C_3 alkyl;

R^3 is hydrogen, fluoro, or methyl;

when X is $-C(R^4)=$, R^4 is hydrogen, fluoro, or methyl, provided that no more than one of R^3 and R^4 may be other than hydrogen; and

R^5 is hydrogen, methyl, or ethyl.

12. The method according to Claim 11 wherein the mammal is a human.

13. A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

X is $-C(R^4)=$ or $-N=$;

Ar is phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^1 and R^2 are independantly hydrogen or C_1-C_3 alkyl;

R^3 is hydrogen, fluoro, or methyl;

when X is $-C(R^4)=$, R^4 is hydrogen, fluoro, or methyl, provided that no more than one of R^3 and R^4 may be other than hydrogen; and

R^5 is hydrogen, methyl, or ethyl.

14. The method according to Claim 13 wherein the mammal is a human.

15. A compound according to any one of Claims 1 - 7 for use as a pharmaceutical.

16. A compound according to any one of Claims 1 - 7 for use in activating 5-HT_{1F} receptors in a mammal.

17. A compound according to any one of Claims 1 - 7 for use in inhibiting dural protein extravasation in a mammal.

18. A compound according to any one of Claims 1 - 7 for use in the treatment or prevention of migraine in a mammal.

19. A compound according to any one of Claims 16-18 wherein the mammal is a human.

20. The use of a compound according to any one of Claims 1 - 7 in the manufacture of a medicament for the activation of 5-HT_{1F} receptors in a mammal.

21. The use of a compound according to any one of Claims 1 - 7 in the manufacture of a medicament for the inhibition of dural protein extravasation in a mammal.

22. The use of a compound according to any one of Claims 1 - 7 in the manufacture of a medicament for the treatment or prevention of migraine in a mammal.

23. The use of a compound according to any one of Claims 1 - 7 in the manufacture of a medicament for the treatment of a disorder associated with dysfunction of the 5-HT_{1F} receptors in a mammal.

24. The use according to Claim 23 wherein the 5-HT_{1F} receptor associated disorder is dural protein extravasation.

25. The use according to Claim 26 wherein the 5-HT_{1F} receptor associated disorder is migraine.

26. The use according to any one of Claims 20–25 wherein the mammal is a human.

27. A pharmaceutical composition adapted for the treatment or prevention of migraine comprising a compound according to any one of Claims 1 - 7 in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents therefore.